CoChat
Sign Up
Cited by 14Cancer-related molecular mechanisms researchMicroRNA in disease regulationRNA modifications and cancer

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Small Non-Coding RNAs in Leukemia

Open access
Balatti, Veronica, Croce, Carlo M.·2022·Cancers
DOI 10.3390/cancers14030509PMC PMC8833386
Open this paper in CoChat — free accountOpen PDF

Abstract

In 2020, more than 60,500 people were diagnosed with leukemia in the USA, and more than 23,000 died. The incidence of leukemia is still rising, and drug resistance development is a serious concern for patients' wellbeing and survival. In the past two decades, small non-coding RNAs have been studied to evaluate their functions and possible role in cancer pathogenesis. Small non-coding RNAs are short RNA molecules involved in several cellular processes by regulating the expression of genes. An increasing body of evidence collected by many independent studies shows that the expression of these molecules is tissue specific, and that their dysregulation alters the expression of genes involved in tumor development, progression and drug response. Indeed, small non-coding RNAs play a pivotal role in the onset, staging, relapse and drug response of hematological malignancies and cancers in general. These findings strongly suggest that small non-coding RNAs could function as biomarkers and possible targets for therapy. Thus, in this review, we summarize the regulatory mechanisms of small non-coding RNA expression in different types of leukemia and assess their potential clinical implications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14030509

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Noncoding RNAs can influence the expression of other genes through multiple mechanisms to cause a wide range of disorders.

    “they can influence the expression of other genes through multiple mechanisms to cause a wide range of disorders.215–218”

    From Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential (2023) · cites this paper as [215]

    The miRNA Biogenesis section describes how small non-coding RNAs regulate gene expression through mRNA degradation or inhibition of translation. The Background and CLL sections link their dysregulation to leukemia and other cancers, but the paper does not establish the claim’s broader scope of a wide range of disorders. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 129

  1. Preisler, 1994, The leukemias, Dis. Mon., 40, 525, 10.1016/0011-5029(94)90015-9 · DOI
  2. Ferreri, 2016, Chronic lymphocytic leukaemia, Crit. Rev. Oncol. Hematol., 104, 169, 10.1016/j.critrevonc.2016.06.003 · DOI
  3. Onciu, 2009, Acute lymphoblastic leukemia, Hematol. Oncol. Clin. N. Am., 23, 655, 10.1016/j.hoc.2009.04.009 · DOI
  4. Hunger, 2015, Acute Lymphoblastic Leukemia in Children, N. Engl. J. Med., 373, 1541, 10.1056/NEJMra1400972 · DOI
  5. Saultz, J.N., and Garzon, R. (2016). Acute Myeloid Leukemia: A Concise Review. J. Clin. Med., 5. · DOI
  6. Faderl, 1999, The biology of chronic myeloid leukemia, N. Engl. J. Med., 341, 164, 10.1056/NEJM199907153410306 · DOI
  7. Taylor, 2017, Diagnosis and classification of hematologic malignancies on the basis of genetics, Blood, 130, 410, 10.1182/blood-2017-02-734541 · DOI
  8. Kelly, 2002, Comprehensive genotypic analysis of leukemia: Clinical and therapeutic implications, Curr. Opin Oncol., 14, 10, 10.1097/00001622-200201000-00003 · DOI
  9. Nowell, 1986, Chromosomal approaches to the molecular basis of neoplasia, Symp. Fundam Cancer Res., 39, 17
  10. Rowley, 1984, Biological implications of consistent chromosome rearrangements in leukemia and lymphoma, Cancer Res., 44, 3159
  11. Nowell, 1960, A minute chromosome in human chronic granulocytic leukemia, Landmarks Med. Genet. Class. Pap. Comment., 132, 1497
  12. Garofalo, M., Quintavalle, C., Zanca, C., De Rienzo, A., Romano, G., Acunzo, M., Puca, L., Incoronato, M., Croce, C.M., and Condorelli, G. (2008). Akt regulates drug-induced cell death through Bcl-w downregulation. PLoS ONE, 3. · DOI
  13. Haldar, 1995, Inactivation of Bcl-2 by phosphorylation, Proc. Natl. Acad. Sci. USA, 92, 4507, 10.1073/pnas.92.10.4507 · DOI
  14. Croce, 2016, Finally, An Apoptosis-Targeting Therapeutic for Cancer, Cancer Res., 76, 5914, 10.1158/0008-5472.CAN-16-1248 · DOI
  15. Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
  16. Calin, 2005, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia, N. Engl. J. Med., 353, 1793, 10.1056/NEJMoa050995 · DOI
  17. Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc. Natl. Acad. Sci. USA, 102, 13944, 10.1073/pnas.0506654102 · DOI
  18. Pekarsky, 2006, Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181, Cancer Res., 66, 11590, 10.1158/0008-5472.CAN-06-3613 · DOI
  19. Calin, 2006, MicroRNA signatures in human cancers, Nat. Rev. Cancer, 6, 857, 10.1038/nrc1997 · DOI
  20. Aqeilan, 2010, miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives, Cell Death Differ., 17, 215, 10.1038/cdd.2009.69 · DOI
  21. Balatti, 2019, MicroRNA dysregulation and multi-targeted therapy for cancer treatment, Adv. Biol. Regul., 75, 100669, 10.1016/j.jbior.2019.100669 · DOI
  22. Pekarsky, 2019, Noncoding RNA genes in cancer pathogenesis, Adv. Biol. Regul., 71, 219, 10.1016/j.jbior.2018.12.002 · DOI
  23. Pekarsky, 2016, Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer, Proc. Natl. Acad. Sci. USA, 113, 5071, 10.1073/pnas.1604266113 · DOI
  24. Balatti, 2015, TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 112, 2169, 10.1073/pnas.1500010112 · DOI
  25. Liu, 2008, Expression profiling of microRNA using oligo DNA arrays, Methods, 44, 22, 10.1016/j.ymeth.2007.10.010 · DOI · Paper page
  26. Balatti, V., Nigita, G., Veneziano, D., Drusco, A., Stein, G.S., Messier, T.L., Farina, N.H., Lian, J.B., Tomasello, L., and Liu, C.-G. (2017). TsRNA signatures in cancer. Proc. Natl. Acad. Sci. USA, in press. · DOI
  27. Krishnan, 2016, Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer, Oncotarget, 7, 37944, 10.18632/oncotarget.9272 · DOI
  28. Esteller, 2011, Non-coding RNAs in human disease, Nat. Rev. Genet., 12, 861, 10.1038/nrg3074 · DOI · Paper page
  29. Kim, 2005, MicroRNA biogenesis: Coordinated cropping and dicing, Nat. Rev. Mol. Cell Biol., 6, 376, 10.1038/nrm1644 · DOI · Paper page
  30. Winter, 2009, Many roads to maturity: MicroRNA biogenesis pathways and their regulation, Nat. Cell Biol., 11, 228, 10.1038/ncb0309-228 · DOI
  31. Grimson, 2007, MicroRNA targeting specificity in mammals: Determinants beyond seed pairing, Mol. Cell, 27, 91, 10.1016/j.molcel.2007.06.017 · DOI · Paper page
  32. Hata, 2016, Dysregulation of microRNA biogenesis machinery in cancer, Crit. Rev. Biochem. Mol. Biol., 51, 121, 10.3109/10409238.2015.1117054 · DOI
  33. Claus, 2012, Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia, J. Clin. Oncol., 30, 2483, 10.1200/JCO.2011.39.3090 · DOI
  34. Stilgenbauer, 2000, Genomic aberrations and survival in chronic lymphocytic leukemia, N. Engl. J. Med., 343, 1910, 10.1056/NEJM200012283432602 · DOI
  35. Zenz, 2011, Importance of genetics in chronic lymphocytic leukemia, Blood Rev., 25, 131, 10.1016/j.blre.2011.02.002 · DOI
  36. Kay, 2007, The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia, Leukemia, 21, 1885, 10.1038/sj.leu.2404802 · DOI
  37. Morilla, 2008, Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL, Leuk Lymphoma, 49, 2108, 10.1080/10428190802360810 · DOI
  38. Pekarsky, 2018, BCL2 and miR-15/16: From gene discovery to treatment, Cell Death Differ., 25, 21, 10.1038/cdd.2017.159 · DOI
  39. Scrideli, 2012, Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features, Leuk Res., 36, 293, 10.1016/j.leukres.2011.10.005 · DOI
  40. Li, 2013, MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways, Br J. Cancer, 109, 2189, 10.1038/bjc.2013.562 · DOI
  41. Balatti, 2018, miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients, Blood, 132, 2179, 10.1182/blood-2018-04-845115 · DOI
  42. Swellam, 2018, Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia, Biochem. Genet., 56, 283, 10.1007/s10528-018-9844-y · DOI
  43. Flamant, 2010, Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia, Haematologica, 95, 1325, 10.3324/haematol.2009.020636 · DOI
  44. Burda, 2011, Expression patterns of microRNAs associated with CML phases and their disease related targets, Mol. Cancer, 10, 41, 10.1186/1476-4598-10-41 · DOI
  45. Suresh, 2011, MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML, J. Cell Commun. Signal, 5, 183, 10.1007/s12079-011-0139-x · DOI
  46. McLaughlin, 2007, Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics, Proc. Natl. Acad. Sci. USA, 104, 20501, 10.1073/pnas.0710532105 · DOI
  47. Ferreira, 2014, ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance, Blood Cells Mol. Dis., 53, 47, 10.1016/j.bcmd.2014.02.008 · DOI
  48. Bueno, 2008, Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression, Cancer Cell, 13, 496, 10.1016/j.ccr.2008.04.018 · DOI
  49. Srutova, 2018, BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia, Haematologica, 103, 2016, 10.3324/haematol.2018.193086 · DOI
  50. Jabbour, 2018, Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring, Am. J. Hematol., 93, 442, 10.1002/ajh.25011 · DOI
  51. Rassenti, 2017, MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 114, 10731, 10.1073/pnas.1708264114 · DOI
  52. Lovat, 2020, Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia, Proc. Natl. Acad. Sci. USA, 117, 12332, 10.1073/pnas.2003597117 · DOI
  53. Lovat, 2015, miR-15b/16-2 deletion promotes B-cell malignancies, Proc. Natl. Acad. Sci. USA, 112, 11636, 10.1073/pnas.1514954112 · DOI
  54. Lovat, 2018, Knockout of both miR-15/16 loci induces acute myeloid leukemia, Proc. Natl. Acad. Sci. USA, 115, 13069, 10.1073/pnas.1814980115 · DOI
  55. Li, 2008, Distinct microRNA expression profiles in acute myeloid leukemia with common translocations, Proc. Natl. Acad. Sci. USA, 105, 15535, 10.1073/pnas.0808266105 · DOI
  56. Yang, Y.L., Yen, C.T., Pai, C.H., Chen, H.Y., Yu, S.L., Lin, C.Y., Hu, C.Y., Jou, S.T., Lin, D.T., and Lin, S.R. (2015). A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia. PLoS ONE, 10. · DOI
  57. Wang, 2016, MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation, Thorac. Cancer, 7, 279, 10.1111/1759-7714.12325 · DOI
  58. Nabhan, 2017, MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia, Gene, 628, 253, 10.1016/j.gene.2017.07.052 · DOI
  59. Haque, S., and Vaiselbuh, S.R. (2020). Silencing of Exosomal miR-181a Reverses Pediatric Acute Lymphocytic Leukemia Cell Proliferation. Pharmaceuticals, 13. · DOI
  60. Visone, 2011, miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia, Blood, 118, 3072, 10.1182/blood-2011-01-333484 · DOI
  61. Zanette, 2013, Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia, Exp. Hematol. Oncol., 2, 10, 10.1186/2162-3619-2-10 · DOI
  62. Santanam, 2010, Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression, Proc. Natl. Acad. Sci. USA, 107, 12210, 10.1073/pnas.1007186107 · DOI
  63. Ngankeu, 2018, Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia, Oncotarget, 9, 4354, 10.18632/oncotarget.23150 · DOI
  64. Zaidi, 2017, An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells, Oncotarget, 8, 39994, 10.18632/oncotarget.18127 · DOI
  65. Zenz, 2009, miR-34a as part of the resistance network in chronic lymphocytic leukemia, Blood, 113, 3801, 10.1182/blood-2008-08-172254 · DOI
  66. Russ, 2013, Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance, Leukemia, 27, 353, 10.1038/leu.2012.208 · DOI
  67. Weng, 2015, The pathological role and prognostic impact of miR-181 in acute myeloid leukemia, Cancer Genet, 208, 225, 10.1016/j.cancergen.2014.12.006 · DOI
  68. Fabbri, 2011, Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia, JAMA, 305, 59, 10.1001/jama.2010.1919 · DOI
  69. Cuneo, 2002, Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance, Haematologica, 87, 44
  70. Skowronska, 2012, ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele, Haematologica, 97, 142, 10.3324/haematol.2011.048827 · DOI
  71. Greipp, 2013, Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis, Br. J. Haematol., 163, 326, 10.1111/bjh.12534 · DOI
  72. Lin, 2013, The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p, Br. J. Haematol., 160, 53, 10.1111/bjh.12092 · DOI
  73. Puiggros, 2018, Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia, Leuk Lymphoma, 59, 633, 10.1080/10428194.2017.1349901 · DOI
  74. Calin, 2008, MiR-15a and miR-16-1 cluster functions in human leukemia, Proc. Natl. Acad. Sci. USA, 105, 5166, 10.1073/pnas.0800121105 · DOI
  75. Robinson, 2009, Rethinking the central dogma: Noncoding RNAs are biologically relevant, Urol. Oncol., 27, 304, 10.1016/j.urolonc.2008.11.004 · DOI
  76. Veronese, 2015, Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia, Leukemia, 29, 86, 10.1038/leu.2014.139 · DOI
  77. Zenz, 2008, Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway, Cell Cycle, 7, 3810, 10.4161/cc.7.24.7245 · DOI
  78. Zenz, 2009, Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial, Blood, 114, 2589, 10.1182/blood-2009-05-224071 · DOI
  79. Visone, 2009, Karyotype-specific microRNA signature in chronic lymphocytic leukemia, Blood, 114, 3872, 10.1182/blood-2009-06-229211 · DOI
  80. Visone, 2012, MiR-181b: New perspective to evaluate disease progression in chronic lymphocytic leukemia, Oncotarget, 3, 195, 10.18632/oncotarget.448 · DOI
  81. Bresin, 2015, miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model, Oncotarget, 6, 19807, 10.18632/oncotarget.4415 · DOI
  82. Haussecker, 2010, Human tRNA-derived small RNAs in the global regulation of RNA silencing, RNA, 16, 673, 10.1261/rna.2000810 · DOI
  83. Veneziano, 2019, Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 116, 24252, 10.1073/pnas.1913695116 · DOI
  84. Croce, 2017, Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy, Advances in Cancer Research, 135, 173, 10.1016/bs.acr.2017.06.007 · DOI
  85. Pepe, F., and Balatti, V. (2020). Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. J. Clin. Med., 9. · DOI
  86. Willemse, 2002, Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL, Blood, 99, 4386, 10.1182/blood.V99.12.4386 · DOI
  87. Copelan, 1995, The biology and treatment of acute lymphoblastic leukemia in adults, Blood, 85, 1151, 10.1182/blood.V85.5.1151.bloodjournal8551151 · DOI
  88. Malard, 2020, Acute lymphoblastic leukaemia, Lancet, 395, 1146, 10.1016/S0140-6736(19)33018-1 · DOI
  89. Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 · DOI
  90. Terwilliger, 2017, Acute lymphoblastic leukemia: A comprehensive review and 2017 update, Blood Cancer J., 7, e577, 10.1038/bcj.2017.53 · DOI
  91. Schotte, 2009, Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia, Leukemia, 23, 313, 10.1038/leu.2008.286 · DOI
  92. Almeida, 2019, MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia, Hematol. Oncol., 37, 103, 10.1002/hon.2567 · DOI
  93. Luan, 2015, The functional role of microRNA in acute lymphoblastic leukemia: Relevance for diagnosis, differential diagnosis, prognosis, and therapy, Onco. Targets Ther., 8, 2903
  94. Fulci, 2009, Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles, Genes Chromosomes Cancer, 48, 1069, 10.1002/gcc.20709 · DOI
  95. Mavrakis, 2011, A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL), Nat. Genet., 43, 673, 10.1038/ng.858 · DOI
  96. Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI
  97. Verduci, 2015, microRNA-181a enhances cell proliferation in acute lymphoblastic leukemia by targeting EGR1, Leuk Res., 39, 479, 10.1016/j.leukres.2015.01.010 · DOI
  98. Downing, 1999, Acute myeloid leukemia, N. Engl. J. Med., 341, 1051, 10.1056/NEJM199909303411407 · DOI
  99. Stubbins, 2021, Differentiation therapy for myeloid malignancies: Beyond cytotoxicity, Blood Cancer J., 11, 193, 10.1038/s41408-021-00584-3 · DOI
  100. Rosenfeld, 2000, A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies, Leukemia, 14, 2, 10.1038/sj.leu.2401618 · DOI
  101. Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 · DOI
  102. 2016, Acute myeloid leukemia: A comprehensive review and 2016 update, Blood Cancer J., 6, e441, 10.1038/bcj.2016.50 · DOI
  103. Kumar, 2011, Genetic abnormalities and challenges in the treatment of acute myeloid leukemia, Genes Cancer, 2, 95, 10.1177/1947601911408076 · DOI
  104. Estey, 2006, Acute myeloid leukaemia, Lancet, 368, 1894, 10.1016/S0140-6736(06)69780-8 · DOI
  105. Zampini, 2018, Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML, Leukemia, 32, 1124, 10.1038/s41375-017-0003-y · DOI
  106. Meyer, 2018, The MLL recombinome of acute leukemias in 2017, Leukemia, 32, 273, 10.1038/leu.2017.213 · DOI
  107. Soni, 2015, Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia, Leuk Lymphoma, 56, 3236, 10.3109/10428194.2015.1036262 · DOI
  108. Garzon, 2008, MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia, Blood, 111, 3183, 10.1182/blood-2007-07-098749 · DOI
  109. Garzon, 2009, MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1, Blood, 113, 6411, 10.1182/blood-2008-07-170589 · DOI
  110. Gong, 2014, The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia, Cell Death Differ., 21, 100, 10.1038/cdd.2013.133 · DOI
  111. Pulikkan, 2010, C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations, Blood, 116, 5638, 10.1182/blood-2010-04-281600 · DOI
  112. Schwind, 2010, Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study, J. Clin. Oncol., 28, 5257, 10.1200/JCO.2010.29.2953 · DOI
  113. Marcucci, 2008, Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B Study, J. Clin. Oncol., 26, 5078, 10.1200/JCO.2008.17.5554 · DOI
  114. Li, 2012, Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML, Blood, 119, 2314, 10.1182/blood-2011-10-386235 · DOI
  115. Lu, 2014, miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1, Int. J. Oncol., 45, 383, 10.3892/ijo.2014.2390 · DOI
  116. Rowley, 1973, Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, 243, 290, 10.1038/243290a0 · DOI · Paper page
  117. Melo, 1996, The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype, Blood, 88, 2375, 10.1182/blood.V88.7.2375.bloodjournal8872375 · DOI
  118. Pendergast, 1993, BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein, Cell, 75, 175, 10.1016/S0092-8674(05)80094-7 · DOI
  119. Jabbour, 2014, Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia, Leuk Lymphoma, 55, 1451, 10.3109/10428194.2013.845883 · DOI
  120. Melo, 2007, Chronic myeloid leukaemia as a model of disease evolution in human cancer, Nat. Rev. Cancer, 7, 441, 10.1038/nrc2147 · DOI
  121. Vigneri, 2001, Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase, Nat. Med., 7, 228, 10.1038/84683 · DOI
  122. 2008, Part I: Milestones in personalised medicine--imatinib, Lancet Oncol., 9, 600, 10.1016/S1470-2045(08)70152-9 · DOI
  123. Hughes, 2003, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia, N. Engl. J. Med., 349, 1423, 10.1056/NEJMoa030513 · DOI
  124. Soverini, 2005, ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia, J. Clin. Oncol., 23, 4100, 10.1200/JCO.2005.05.531 · DOI
  125. Alves, 2019, MicroRNA signature refine response prediction in CML, Sci. Rep., 9, 9666, 10.1038/s41598-019-46132-9 · DOI
  126. Agirre, 2008, Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth, Mol. Cancer Res., 6, 1830, 10.1158/1541-7786.MCR-08-0167 · DOI
  127. Garate, 2009, MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations, Mol. Cancer, 8, 69, 10.1186/1476-4598-8-69 · DOI
  128. Lovat, F., Gasparini, P., Nigita, G., Larkin, K., Byrd, J.C., Minden, M.D., Andreeff, M., Carter, B.Z., and Croce, C.M. (2021). Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc. Natl. Acad. Sci. USA, 118. · DOI
  129. Tsujimoto, 1984, Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation, Science, 226, 1097, 10.1126/science.6093263 · DOI

Cited by

Sorted by citations

Metadata

Authors
Balatti, V., & Croce, C. M.
Affiliations
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Corresponding author
  • Balatti, Veronica
  • Croce, Carlo M.
ORCID
Croce, Carlo M.
Venue
Cancers
Publisher
MDPI AG
Published
2022-01-20
Volume
14
Issue
3
Pages
509
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers14030509
PMC
PMC8833386
OpenAlex
W4206981002
Cited by
14
References
1
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 3
FWCI
0.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords
small RNA, leukemia, microRNA, drug resistance, hematologic malignancies, biomarkers, therapeutic target, gene expression regulation, tumor progression, relapse

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review